<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061603</url>
  </required_header>
  <id_info>
    <org_study_id>CS-200</org_study_id>
    <nct_id>NCT04061603</nct_id>
  </id_info>
  <brief_title>iCLAS™ for Persistent Atrial Fibrillation</brief_title>
  <official_title>iCLAS™ for Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagio Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagio Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System&#xD;
      (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF).&#xD;
      Data will be used to support a pre-market application (PMA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A staged pre-market, single-arm, clinical study designed to collect acute and long-term&#xD;
      safety and efficacy data for the Adagio AF Cryoablation System (iCLAS™). Patient population&#xD;
      will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure.&#xD;
      Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will&#xD;
      receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment&#xD;
      at one, three, six, and twelve months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 9, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 9, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Symptomatic persistent atrial fibrillation that failed at least one class I or Class III AAD with no prior history of ablation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure.</measure>
    <time_frame>12-months</time_frame>
    <description>MAEs include any of the following:&#xD;
Death&#xD;
Myocardial infarction&#xD;
Cardiac perforation/pericardial tamponade&#xD;
Cerebral infarct or systemic embolism&#xD;
Major bleeding requiring transfusion of blood products&#xD;
Mitral or tricuspid valve damage&#xD;
Symptomatic pulmonary vein stenosis&#xD;
Severe (≥ 70%) pulmonary vein stenosis&#xD;
Permanent phrenic nerve injury&#xD;
Access site complications requiring pharmacological or surgical intervention&#xD;
Atrio-esophageal fistula&#xD;
Pericarditis&#xD;
Heart block requiring a permanent pacemaker&#xD;
Vagal nerve injury with GI dysmotility&#xD;
Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as &quot;probably or definitely related&quot; to the Adagio System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT).</measure>
    <time_frame>12-months</time_frame>
    <description>The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recording and analysis of all identified SAEs and SADEs through 12-months post-procedure.</measure>
    <time_frame>12-months</time_frame>
    <description>Events will be sub-stratified based on time to event as follows:&#xD;
Early onset (procedure through 7-days post-ablation)&#xD;
Peri-procedure (&gt; 7-days through 30-days post-ablation)&#xD;
Late onset (&gt;30-days post ablation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the proportion of subjects with acute procedural (ablation) success</measure>
    <time_frame>20-minutes following last ablation</time_frame>
    <description>Documentation of pulmonary vein isolation and posterior wall isolation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>iCLAS Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablation of the left and right atrium with the Adagio Medical iCLAS System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adagio AF Cryoablation System (iCLAS™)</intervention_name>
    <description>Endovascular ablation of the left and right atrium</description>
    <arm_group_label>iCLAS Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        IC1 Male or female between the ages of 18 and 80 years&#xD;
&#xD;
        IC2 Currently scheduled for an ablation of symptomatic, PsAF defined as continuous AF that&#xD;
        is sustained &gt; 7-days and ≤ 12 months and documented by the following: a. Physician's note&#xD;
        indicating continuous AF &gt; 7 days and ≤ 12 months, AND b. One of the following: i. 24-hour&#xD;
        Holter within 180 days of enrollment showing continuous AF, OR ii. Two electrocardiograms&#xD;
        from any forms of rhythm monitoring (e.g., 12-lead ECGs or single lead ECGs) completed ≥ 7&#xD;
        days apart within 180 days of enrollment.&#xD;
&#xD;
        IC3 Refractory to at least one class I or III AAD. (Refractory defined as not effective,&#xD;
        not tolerated or not desired)&#xD;
&#xD;
        IC4 Willingness, ability and commitment to participate in baseline and follow-up&#xD;
        evaluations for the full length of the study&#xD;
&#xD;
        IC5 Willingness and ability to give an informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        EC 1 In the opinion of the Investigator, any known contraindication to an atrial ablation,&#xD;
        TEE, or anticoagulation. Including, but not limited to, the identification of any atrial&#xD;
        thrombus or evidence of sepsis&#xD;
&#xD;
        EC 2 Any duration of continuous AF lasting longer than 12-months&#xD;
&#xD;
        EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT&#xD;
&#xD;
        EC 4 Atrial fibrillation secondary to electrolyte imbalance, active thyroid disease, or any&#xD;
        other reversible or non-cardiac cause&#xD;
&#xD;
        EC 5 Structural heart disease as described below:&#xD;
&#xD;
          1. Left ventricular ejection fraction (LVEF) &lt; 40% based on most recent TTE&#xD;
&#xD;
          2. Left atrial size &gt; 55 mm (parasternal long axis view) documented within 6-months of&#xD;
             screening&#xD;
&#xD;
          3. NYHA Class III or IV heart failure documented within the previous 12-months&#xD;
&#xD;
          4. An implanted pacemaker or ICD&#xD;
&#xD;
          5. Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for CABG),&#xD;
&#xD;
          6. Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve&#xD;
&#xD;
          7. Interatrial baffle, closure device, patch, or PFO occluder&#xD;
&#xD;
          8. Presence of a left atrial appendage occlusion device&#xD;
&#xD;
          9. Presence of any pulmonary vein stenting devices&#xD;
&#xD;
         10. Coronary artery bypass graft (CABG) or PTCA procedure within 6 months prior to&#xD;
             procedure&#xD;
&#xD;
         11. Unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
         12. Myocardial infarction within the previous six (6) months prior to procedure&#xD;
&#xD;
         13. Moderate or severe mitral insufficiency or stenosis based on most recent TTE&#xD;
&#xD;
         14. Atrial myxoma&#xD;
&#xD;
         15. Significant congential anomaly&#xD;
&#xD;
        EC 6 BMI &gt; 40&#xD;
&#xD;
          -  BMI &gt;35 and no prior sponsor approval into the study&#xD;
&#xD;
        EC 7 Any previous history of cryoglobulinemia&#xD;
&#xD;
        EC 8 History of blood clotting or bleeding disease&#xD;
&#xD;
        EC 9 History of severe COPD requiring steroid use in the previous 12-months&#xD;
&#xD;
        EC 10 History of severe sleep apnea (AHI &gt; 30) not currently treated with a CPAP machine or&#xD;
        other mechanical device&#xD;
&#xD;
        EC 11 Any prior history of documented cerebral infarct including recent TIA (within one&#xD;
        year) or systemic embolism (excluding a post-operative DVT)&#xD;
&#xD;
        EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis&#xD;
&#xD;
        EC 13 Pregnant or lactating (current or anticipated during study follow-up)&#xD;
&#xD;
        EC 14 Current enrollment in any other study protocol where testing or results from that&#xD;
        study may interfere with the procedure or outcome measurements for this study&#xD;
&#xD;
        EC 15 Any other condition that, in the judgment of the investigator, makes the patient a&#xD;
        poor candidate for this procedure, the study or compliance with the protocol (includes&#xD;
        vulnerable patient population, mental illness, addictive disease, terminal illness with a&#xD;
        life expectancy of less than two years, extensive travel away from the research center,&#xD;
        COVID-19 related concerns)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erum S Shaikh</last_name>
    <phone>949-348-1188</phone>
    <email>eshaikh@adagiomedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nabil Jubran</last_name>
    <phone>949-348-1188</phone>
    <phone_ext>207</phone_ext>
    <email>njubran@adagiomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Burns, BSN, RN</last_name>
      <phone>205-971-7500</phone>
      <email>karen.burns@grandviewhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jose Osorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gustavo Morales, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anil Rajendra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Schohn</last_name>
      <phone>419-494-7257</phone>
      <email>james.schohn@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Wilber Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Zawaneh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Rubino</last_name>
      <phone>870-935-6729</phone>
      <email>krubino@dnairresearch.com</email>
    </contact>
    <investigator>
      <last_name>Devi Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioanna Loupasi</last_name>
      <email>iloupasi@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Frederick Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Feld, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Wimmer</last_name>
      <phone>303-715-2275</phone>
      <email>rwimmer@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Srikanth Sundaram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Alyesh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Choe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indira Becerrit</last_name>
      <phone>904-953-4832</phone>
      <email>becerrit.indira@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Fred Kusumoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kalpathi Venkatachalam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryam Haydari</last_name>
      <email>maryam.heydari@emory.edu</email>
    </contact>
    <investigator>
      <last_name>David De Lurgio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Lloyd, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Carswell</last_name>
      <phone>312-926-7554</phone>
      <email>amy.carswell@nm.org</email>
    </contact>
    <investigator>
      <last_name>Bradley Knight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rod Passman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Heart Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bainter</last_name>
      <phone>217-492-9100</phone>
      <email>lbainter@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Mark Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Grubb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Martucci</last_name>
      <phone>410-502-0517</phone>
      <email>mmill148@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Avara</last_name>
      <phone>410-502-5616</phone>
      <email>kavara1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hugh Calkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronald Berger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunil Sinha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Spragg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hiroshi Ashikaga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Joseph Marine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Ha</last_name>
      <phone>347-213-0290</phone>
      <email>Gha2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Moussa Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Heist, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Michel</last_name>
      <phone>201-447-8453</phone>
      <email>kmichel@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dan Musat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cordova</last_name>
      <phone>505-843-2871</phone>
      <email>jennifer.cordova@lovelace.com</email>
    </contact>
    <investigator>
      <last_name>Michael Hoskins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean Mazer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Bestawros, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Belcher</last_name>
      <phone>614-788-3876</phone>
      <email>Christina.Belcher@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Sreedhar Billakanty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Harold</last_name>
      <phone>713-798-1037</phone>
      <email>harold@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Abdi Rasekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi Razavi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Saeed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedwig Batjeons</last_name>
      <phone>+3253724168</phone>
      <email>hedwig.batjeons@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Tom De Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.P. Coenen - Vrijhoeven</last_name>
      <email>j.coenen-vrijhoeven@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Bruno Schwagten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Medical Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Nath</last_name>
      <phone>905-895-4521</phone>
      <email>anath@southlakeregional.org</email>
    </contact>
    <investigator>
      <last_name>Atul Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaariv Khaykin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joke Helwig</last_name>
      <email>j.helwig@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Lucas Boersma, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Schotte</last_name>
      <email>g.schotte@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Tamas Szili-Torok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

